Skip to main content

United States Financial

Bloomberg
Financial

Novartis and Boston Scientific Slide, Intel Price Hikes | Stock Movers

On this episode of Stock Movers: - Novartis (NOVN) shares are lower as it suffered its third clinical-trial setback in a week after a treatment for a rare muscle-wasting disease failed a late-stage study. - Boston Scientific (BSX) shares are moving on news it said that fallout from a cybersecurity incident has impacted its ability to ship its products to customers and will cause the medical devices company to miss its sales growth and earnings estimates for the year. - Intel (INTC) is rising on a report that the company could raise computer chip prices next month.

Read more: Novartis and Boston Scientific Slide, Intel Price Hikes | Stock Movers
Bloomberg
Financial

Stock Resiliency Depends on Moves by the Fed, Says Principal's Shah

"The next couple of months are likely to be pretty rocky with only modest gains to be had for the rest of the year," says Seema Shah, chief global strategist at Principal Asset Management. Shah says a possible series of hikes by the Federal Reserve can provide some resistance for equities.

Read more: Stock Resiliency Depends on Moves by the Fed, Says Principal's Shah
Bloomberg
Financial

Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

Novartis saw a treatment for a rare muscle-wasting disease fail a late-stage study, the third clinical-trial setback in a week. The medicine was the centerpiece of Novartis's $12 billion takeover of Avidity Biosciences and raises questions about the drugmaker's growth prospects. Fabienne Kinzelmann reports on Bloomberg Television.

Read more: Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback